Plant ID: NPO25118
Plant Latin Name: Centaurea benedicta
Taxonomy Genus: Centaurea
Taxonomy Family: Asteraceae
NCBI TaxonomyDB:
50282
Plant-of-the-World-Online:
n.a.
Turkey; Madagascar; Angola; South Africa; Zimbabwe; Swaziland; Bulgaria
ADRA2C; CNR1; ADRA2A; CNR2; | |
NMUR2; | |
GAA; ACHE; | |
MAPK1; | |
RXRA; | |
ALOX5; | |
MMP2; | |
POLB; |
Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Nuclear hormone receptor subfamily 2 group B | RXRA | Retinoid X receptor alpha | P19793 | CHEMBL2061 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | CNR1 | Cannabinoid CB1 receptor | P21554 | CHEMBL218 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.121E-06 | 5.774E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.121E-06 | 5.774E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0038171; cannabinoid signaling pathway | 2.121E-06 | 5.774E-03 | CNR1, CNR2 |
MF | GO:0060089; molecular transducer activity | GO:0004949; cannabinoid receptor activity | 1.061E-06 | 5.774E-03 | CNR1, CNR2 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.061E-06 | 5.774E-03 | ADRA2A, ADRA2C |
BP | GO:0032501; multicellular organismal process | GO:0019233; sensory perception of pain | 4.217E-06 | 7.063E-03 | CNR1, CNR2, MAPK1 |
BP | GO:0032501; multicellular organismal process | GO:0006940; regulation of smooth muscle contraction | 7.830E-06 | 1.066E-02 | ADRA2A, ADRA2C, NMUR2 |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 9.886E-06 | 1.196E-02 | ADRA2A, ADRA2C |
MF | Unclassified; | GO:0004871; signal transducer activity | 2.280E-05 | 2.027E-02 | ADRA2A, ADRA2C, CNR1, CNR2, MAPK1, NMUR2, RXRA |
MF | GO:0005488; binding | GO:0031690; adrenergic receptor binding | 5.383E-05 | 3.781E-02 | ADRA2A, ADRA2C |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 3.596E-07 | 3.704E-05 | CNR2, CNR1, NMUR2, ADRA2C, ADRA2A |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 1.190E-04 | 4.559E-03 | MAPK1, ADRA2C, ADRA2A |
09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 1.328E-04 | 4.559E-03 | RXRA, MAPK1 |
09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 4.992E-04 | 1.028E-02 | RXRA, MAPK1 |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.671E-04 | 6.878E-03 | MMP2, MAPK1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.550E-03 | 1.612E-02 | MMP2, MAPK1 |
09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.943E-03 | 1.612E-02 | ACHE, MAPK1 |
09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 1.612E-03 | 1.612E-02 | CNR1, MAPK1 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.978E-03 | 1.612E-02 | ALOX5, MAPK1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.192E-03 | 1.612E-02 | RXRA, MAPK1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | CNR2; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | CNR2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR2; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CNR2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | CNR2; |
C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; MMP2; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR2; ACHE; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
C00-D49: Neoplasms | Cutaneous T-cell lymphoma | C84.0, C84.1 | RXRA; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CNR2; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |